Target / Biomarker
Discovery & Validation
Euretos is an AI (Artificial Intelligence) platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their research. Available as subscription, consulting service or direct access
EURETOS AI PLATFORM
In Silico Multi Omics
Drive your in vitro and in vivo research by in silico multi omics analysis. Ask Euretos and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.
FIND OUT MORE
Researchers find novel gene driving suppression of the immune response by tumorsTuesday 10 October 2017
One of the key areas of cancer research today is understanding how tumors suppress the immune response. In a recent study published in Cell Reports researchers have now identified one of the central players driving this mechanism: the DNMT3A gene. ...
Researchers find novel molecular mechanism driving insulin resistance in type 2 diabetesFriday 22 September 2017
The specific mechanism driving insulin resistance in type 2 diabetes is largely unknown. In a recent article in the Journal of Biological Chemistry, researchers have, for the first time, found the key elements of this important mechanism. The resea ...
Prof David Webb (The Scripps Research Institute)
“The Euretos Knowledge Platform is nothing less than an in silico way to save all drug and biotech researchers an infinite amount of blood, sweat and tears by providing
them with a powerful knowledge discovery platform.
The Euretos Knowledge Platform allows the researcher to rapidly assess whether a given target, research area, etc., is related, even distantly, to another such entity thus allowing one to uncover hidden connections, leading to new knowledge.In the drug discovery arena, this thing is a gold mine.